BioSyent Inc.
BioSyent Inc.
Your view on RX.V
Overview
What the company does, where it operates, and who runs it.
About BioSyent Inc.
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- CEO
- René C. Goehrum
- Headquarters
- 2476 Argentia Road, Mississauga, ON, CA
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- CEO
- René C. Goehrum
- Headquarters
- 2476 Argentia Road, Mississauga, ON, CA
BioSyent Inc., a specialty pharmaceutical company, sources, acquires or in-licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally.
Its products include FeraMAX 150, an oral hematinic; FeraMAX Powder, a water soluble oral iron supplement, which helps the body form red blood cells; and FeraMAX Pd Therapeutic 150 for the prevention and treatment of iron deficiency anemia.
It also offers Cathejell, a product indicated for surface anesthesia and lubrication during various procedures, including cystoscopy, catheterization, endourethral operation, endoscopy, proctoscopy, rectoscopy, and tracheal intubation, as well as used for the symptomatic treatment of pain in connection with cystitis and urethritis; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by menopause, stress, and chemotherapy; and Proktis-M, a rectal suppository for the healing of the anus and rectum.
In addition, it provides Combogesic for moderate acute pain and reduction of fever in adults; Protect-It, a non-chemical food-safe grain insecticide product used as a preventative treatment against insect infestations in stored grains; and Tibella, a hormone replacement therapy to treat vasomotor symptoms due to estrogen deficiency.
The company sells its products through wholesalers and retail pharmacy chains. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006 to reflect its forward focus on the pharmaceutical market. BioSyent Inc. was incorporated in 2006 and is headquartered in Mississauga, Canada.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for BioSyent Inc., and the rating behind it. RX.V last traded at C$7.66, 17.8× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for BioSyent Inc.. Starting points for BioSyent Inc.: P/E 17.8, EPS C$0.87, beta 0.39 — an Medical - Pharmaceuticals name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for BioSyent Inc.. BioSyent Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for BioSyent Inc.. Trailing twelve-month EPS for BioSyent Inc. stands at C$0.87. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for BioSyent Inc.. BioSyent Inc. has reported as a listed company since 2012. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
BioSyent Inc. valued side by side against its closest peers. BioSyent Inc. is measured against Medical - Pharmaceuticals peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold BioSyent Inc., and how their positions are changing. At a C$87.3M market value, institutional positions materially move BioSyent Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by BioSyent Inc. executives and directors. Shares of BioSyent Inc. have traded between C$6.49 and C$8.85 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming BioSyent Inc.. BioSyent Inc. is a C$87.3M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming BioSyent Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for BioSyent Inc.. Coverage tracks BioSyent Inc. within Medical - Pharmaceuticals (Healthcare). Press releases and market coverage, newest first.